CSPC Pharmaceutical wins China clinical trial approval for SYH2059 inhalation therapy

Reuters03-16 18:50
CSPC Pharmaceutical wins China clinical trial approval for SYH2059 inhalation therapy

CSPC said China’s National Medical Products Administration has approved clinical trials for its SYH2059 powder for inhalation, a PDE4B inhibitor. The company said the U.S. FDA also cleared SYH2059 for clinical trials in the U.S. The approved indication in China is interstitial lung disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260316-12053828), on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment